CCCC

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).

Wall Street analysts forecast CCCC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCCC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

C4 Therapeutics Inc revenue for the last quarter amounts to 7.24M USD, increased 138.17 % YoY.

C4 Therapeutics Inc. EPS for the last quarter amounts to -0.37 USD, decreased -9.76 % YoY.

C4 Therapeutics Inc (CCCC) has 110 emplpoyees as of December 15 2025.

Today CCCC has the market capitalization of 317.88M USD.